Scott J Dylla
Overview
Explore the profile of Scott J Dylla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
3179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lochmann T, Floros K, Naseri M, Powell K, Cook W, March R, et al.
Clin Cancer Res
. 2017 Nov;
24(2):360-369.
PMID: 29118061
Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually presenting as extensive disease, carrying a 3% 5-year survival. Despite notable advances in SCLC genomics, new therapies remain elusive, largely...
2.
Cardnell R, Li L, Sen T, Bara R, Tong P, Fujimoto J, et al.
Oncotarget
. 2017 Nov;
8(43):73419-73432.
PMID: 29088717
Small cell lung cancer (SCLC) is a recalcitrant cancer for which no new treatments have been approved in over 30 years. While molecular subtyping now guides treatment selection for patients...
3.
Sharma S, Pourat J, Abdel-Atti D, Carlin S, Piersigilli A, Bankovich A, et al.
Cancer Res
. 2017 May;
77(14):3931-3941.
PMID: 28487384
The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas. Rovalpituzumab teserine (Rova-T; SC16LD6.5) is a first-in-class DLL3-targeted...
4.
Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, et al.
Sci Transl Med
. 2017 Jan;
9(372).
PMID: 28077676
Disease relapse after treatment is common in triple-negative breast cancer (TNBC), ovarian cancer (OVCA), and non-small cell lung cancer (NSCLC). Therapies that target tumor-initiating cells (TICs) should improve patient survival...
5.
Rudin C, Pietanza M, Bauer T, Ready N, Morgensztern D, Glisson B, et al.
Lancet Oncol
. 2016 Dec;
18(1):42-51.
PMID: 27932068
Background: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with...
6.
Jahchan N, Lim J, Bola B, Morris K, Seitz G, Tran K, et al.
Cell Rep
. 2016 Jul;
16(3):644-56.
PMID: 27373157
Small cell lung cancer (SCLC) is a neuroendocrine lung cancer characterized by fast growth, early dissemination, and rapid resistance to chemotherapy. We identified a population of long-term tumor-propagating cells (TPCs)...
7.
Dylla S
Mol Cell Oncol
. 2016 Jun;
3(2):e1101515.
PMID: 27308627
Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug conjugate SC16LD6.5 in high-grade pulmonary neuroendocrine tumors. Elevated expression of DLL3, an inhibitor of Notch...
8.
Saunders L, Bankovich A, Anderson W, Aujay M, Bheddah S, Black K, et al.
Sci Transl Med
. 2015 Aug;
7(302):302ra136.
PMID: 26311731
The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells...
9.
Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, et al.
Clin Cancer Res
. 2015 May;
21(18):4165-73.
PMID: 26015513
Purpose: Triple-negative breast cancer (TNBC) and ovarian cancer each comprise heterogeneous tumors, for which current therapies have little clinical benefit. Novel therapies that target and eradicate tumor-initiating cells (TIC) are...
10.
Anderson W, Boyd M, Aguilar J, Pickell B, Laysang A, Pysz M, et al.
PLoS One
. 2015 May;
10(5):e0125255.
PMID: 25955027
Small cell lung cancer (SCLC) is a devastating disease with limited treatment options. Due to its early metastatic nature and rapid growth, surgical resection is rare. Standard of care treatment...